Metronidazole Milpharm

Metronidazole, the active ingredient in Metronidazole Milpharm, is a nitroimidazole antibiotic presented as an oral tablet for systemic use. It treats infections caused by anaerobic bacteria and certain protozoa, and is commonly prescribed for conditions such as bacterial vaginosis, trichomoniasis, and amoebic dysentery.

GNH USA supplies Metronidazole Milpharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from consistent product availability and regulatory compliance across multiple markets.

Metronidazole is a nitroimidazole antibiotic that targets anaerobic bacteria and protozoal organisms. - Bacterial vaginosis: reduces vaginal discharge and restores normal flora by eliminating anaerobic bacteria. - Trichomoniasis: eradicates Trichomonas vaginalis, relieving infection symptoms. - Amoebic dysentery: clears Entamoeba histolytica from intestinal tissue, treating dysentery. - Anaerobic bacterial infections: controls infections such as intra‑abdominal and pelvic infections caused by anaerobes. - Clostridioides difficile infection: suppresses toxin‑producing C. difficile, aiding resolution of colitis.

Metronidazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild stomach upset often reported. - Metallic taste: transient metallic sensation in the mouth. - Diarrhea: loose stools that may occur during therapy. - Headache: mild to moderate headache.

Serious or Rare Side Effects: - Seizures: rare neurologic events requiring immediate attention. - Peripheral neuropathy: tingling or numbness in extremities. - Stevens‑Johnson syndrome: severe skin reaction with blistering. - Severe allergic reactions: including anaphylaxis, swelling, and rash.

Before initiating therapy, consider patient‑specific factors and monitor for adverse events. - Pregnancy: Category B1; use only if benefit outweighs potential risk. - Liver disease: assess hepatic function; dose adjustment may be required. - Alcohol consumption: avoid alcohol due to disulfiram‑like reaction. - Renal impairment: monitor kidney function and adjust dose if necessary. - Allergic reactions: discontinue if rash, pruritus, or anaphylaxis occurs. - Store below 25°C: keep in original packaging, protect from moisture and heat.

Metronidazole can interact with several medicines; review patient medication lists carefully.

Major Interactions (Avoid): - Alcohol: may cause severe flushing, nausea, and vomiting. - Warfarin: potentiates anticoagulant effect, increasing bleeding risk. - Lithium: can raise lithium levels, leading to toxicity.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may reduce efficacy, consider alternative contraception. - Cimetidine: can increase metronidazole plasma concentrations.